Aptose Biosciences Inc. (OTCPK: APTO.F)
Health Care · Biotechnology · CA
$—
— today · — 1Y
Aptose Biosciences Inc. (OTCPK: APTO.F) operates in the Biotechnology industry within the Health Care sector.
trading between 1.01 and 1.74.
Tweenvest scores Aptose Biosciences Inc. across four factors: quality 6/100. Its strongest factor is quality.
APTO.F price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- —
- P/E
- —
- EPS
- -10.79
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $1.74
- 52-week low
- $1.01
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 14
- Next earnings
- —
About Aptose Biosciences Inc.
Aptose Biosciences Inc. is a clinical-stage biotechnology firm dedicated to discovering and advancing personalized therapeutic solutions for challenging oncology cases, primarily within the United States. Its robust pipeline features several key clinical programs: APTO-253, currently in Phase 1a/b trials, targets patients with relapsed or refractory blood cancers like acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (HR MDS). Another candidate, HM43239, is undergoing Phase 1/2 evaluation for the treatment of relapsed or refractory AML. Aptose is also developing luxeptinib, which is in Phase 1a/b clinical studies for individuals battling relapsed or refractory B-cell malignancies, encompassing chronic lymphocytic leukemia, small lymphocytic lymphoma, various non-Hodgkin's lymphomas, as well as AML and HR MDS. Furthermore, the company is progressing with APL-581, a program centered on a dual bromodomain and extra-terminal domain motif protein and kinase inhibitor. Aptose maintains strategic alliances with CrystalGenomics, Inc. and OHM Oncology. Incorporated in 1986 and headquartered in Toronto, Canada, the company was formerly known as Lorus Therapeutics Inc., changing its name to Aptose Biosciences Inc. in August 2014.
- ISIN
- CA03835T4081
- Founded
- 1986
- Listed since
- Apr 25, 1996
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $464.58B | $262.90 | -1.09% |
| Amgen Inc.NasdaqGS: AMGN | $238.06B | $440.34 | -0.43% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $183.64B | $148.09 | -0.01% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.72B | $547.29 | -1.01% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $81.36B | $814.79 | -2.25% |
| argenx SEENXTBR: ARGX | $65.40B | €897.60 | +2.09% |
| Moderna, Inc.NasdaqGS: MRNA | $59.75B | $149.66 | -5.77% |
| CSL LimitedASX: CSL | $59.19B | AU$172.44 | -0.69% |
Figures last refreshed Aug 18, 2026.